Mipasetamab 

Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

AXL^[1]

ADCT-601 (0.02-9.29 nM；5 天) 对 AXL 阳性 SN12C 细胞和 AXL 阴性 Karpas-299 细胞显示出细胞毒性^[1]。
ADCT-601 (0.83 nM；2-36 小时) 在 SN12C 细胞中时间依赖性地增加 DNA 链间交联水平^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

ADCT-601 (3 mg/kg、6 mg/kg；静脉注射；单剂量) 在非荷瘤雄性 Sprague-Dawley 大鼠中具有安全性和耐受性^[1]。
ADCT-601 (1 mg/kg；静脉注射；每天一次，持续 60 天) 在 MDA-MB-231 TNBC 异种移植模型和 SN12C 肾癌异种移植模型中均对小鼠显示出有效且持续的抗肿瘤活性^[1]。
ADCT-601 (0.075、0.15 或 0.3 mg/kg；静脉注射；每天一次，持续 45 天) 在具有异质 AXL 表达的胰腺癌 PDX 模型 (PAXF1657) 中也呈剂量依赖性^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2361055-48-1

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zammarchi F, et al. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. Mol Cancer Ther. 2022 Apr 1;21(4):582-593.  [Content Brief]